<- Go Home
Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Market Cap
SEK 448.5M
Volume
529.8K
Cash and Equivalents
SEK 309.0M
EBITDA
-SEK 24.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
SEK 6.5M
Profit Margin
73.46%
52 Week High
SEK 40.90
52 Week Low
SEK 6.33
Dividend
N/A
Price / Book Value
0.48
Price / Earnings
-17.42
Price / Tangible Book Value
0.48
Enterprise Value
SEK 143.2M
Enterprise Value / EBITDA
-6.33
Operating Income
-SEK 25.4M
Return on Equity
2.36%
Return on Assets
-2.00
Cash and Short Term Investments
SEK 309.0M
Debt
SEK 3.7M
Equity
SEK 928.7M
Revenue
SEK 8.8M
Unlevered FCF
-SEK 117.9M
Sector
Pharmaceuticals
Category
N/A